Capivasertib and Ipatasertib are oral AKT inhibitors that target all three isoforms of AKT (AKT1, AKT2, and AKT3), inhibiting downstream signaling pathways that promote tumor growth and the survival of breast cancer cells. Here, AKT1 is linked to breast cancer.